Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Rhabdoid Tumor 6Medulloblastoma 6Glioma 6Wilms Tumor 5Sarcoma 5Rhabdomyosarcoma 5Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Lymphoma, Non-Hodgkin 5Histiocytosis, Langerhans-Cell 5Hepatoblastoma 5Ependymoma 5Central Nervous System Neoplasms 5Osteosarcoma 4Sarcoma, Ewing 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neuroendocrine Tumors 2Neoplasm Metastasis 2Multiple Myeloma 2Lung Neoplasms 2Burkitt Lymphoma 2Xanthogranuloma, Juvenile 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rectal Neoplasms 1Non functioning pancreatic endocrine tumor 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Histiocytic Sarcoma 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1erdafitinib 1X-Rays 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Diffusion Tensor Imaging 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Familial ependymoma × Phantoms, Imaging × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡